Diabetes mellitus in older patients under conditions of novel coronavirus infection (COVID-19)
https://doi.org/10.37586/2686-8636-4-2021-414-419
Abstract
The review focuses on the issue of type 2 diabetes mellitus (T2D) in older patients and novel coronavirus infection (COVID-19). In accordance with the analyzed articles, comorbidity, pro-inflammatory state, diminished innate immune response, vascular dysfunction and tendency to thrombosis in people with T2D, contribute to a higher susceptibility to SARS-CoV-2 infection and a poor prognosis. The using of Subetta is possible in add-on therapy for older patients with transient hyperglycemia, insulin resistance and type 2 diabetes mellitus in order to achieve carbohydrate metabolic compensation and improve the quality of life.
About the Authors
S. V. Mustafina
Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
Mustafina Svetlana V., MD, PhD, professor, senior research fellow, Laboratory of Clinical-Populational and Prophylactic Studies on Internal and Endocrine Diseases
Novosibirsk
+7(923)228-97-57
A. P. Kashirina
Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
Kashirina Anastasiia P., junior research fellow, Laboratory of Genetic and Environmental Determinants of the Human Life Cycle
Novosibirsk
+7(923)144-83-78
References
1. Всемирная организация здравоохранения. Дата обращения 22 мая 2021 г. https://www.who.int/ru/news/item/09–12–2020-who-reveals-leading-causes-of-death-and-disabilityworldwide-2000–2019.
2. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения / Р.Г. Оганов, В.И. Симаненков, И.Г. Бакулин [и др.] // Кардиоваскулярная терапия и профилактика. — 2019. — Т. 18. — № 1. — С. 5–66. — DOI: 10.15829/1728–8800–2019–1-5–66.
3. Глобальный доклад по диабету [Global report on diabetes]. Женева: Всемирная организация здравоохранения; 2018. Лицензия: CC BY-NC-SA 3.0 IGO.
4. Шестакова М.В. Сахарный диабет в пожилом возрасте: особенности клиники и лечения. Сахарный диабет. 1999; 2(4): 21–22. https://doi.org/10.14341/2072–0351–6128
5. Всемирная организация здравоохранения. Ситуация по распространению COVID-19 глобально на 22 мая 2021 г. Дата обращения 22.05.2021 г. https://covid19.who.int/
6. Всемирная организация здравоохранения. Ситуация по распространению COVID-19 в Российской Федерации на 22 мая 2021 г. Дата обращения 22.05.2021 г. https://covid19.who.int/region/euro/country/ru
7. Yang J., Zheng Y., Gou X. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. March 12, 2020. https://doi.org/10.1016/j.ijid.2020.03.017
8. Dawei W., Bo Hu, Chang Hu. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China, MD1; JAMA. 2020; 323(11): 1061– 1069. https://doi.org/10.1001/jama.2020.1585
9. Zhou F., Yu T., Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. March 9, 2020. The Lancet 395(10229). https://doi.org/10.1016/S0140–6736(20)30566–3
10. Grasselli G., Zangrillo A., Zanella A. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy JAMA. 2020; 323(16): 1574–1581. https://doi.org/10.1001/jama.2020.5394.
11. Fadini G.P., Morieri M.L., Longato E., Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. Journal of Endocrinological Investigation. 2020; 43: 867–869. https://doi.org/10.1007/s40618–020–01236–2.
12. Chow N., Fleming-Dutra K., Gierke G. et all. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12 — March 28, 2020. https://doi.org/10.15585/mmwr.mm6913e2.
13. Шестакова М.В., Викулова О.К., Исаков М.А., Дедов И.И. Сахарный диабет и COVID-19: анализ клинических исходов по данным регистра сахарного диабета российской федерации. Проблемы Эндокринологии. 2020; 66(1): 35–46. https://doi.org/10.14341/probl12458
14. Калмыкова З.А., Кононенко И.В., Скляник И.А., Шестакова М.В., Мокрышева Н.Г. Гипергликемия и возможные механизмы повреждения -клеток у пациентов с COVID-19. Сахарный диабет. 2020; 23(3): 229–234. https://doi.org/10.14341/DM12485
15. Bode B., Garrett V., Messler J., et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020; 14(4): 813–821. https://doi.org/10.1177/1932296820924469.
16. Yang J.K., Lin S.S., Ji X.J., Guo L.M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010 Sep; 47(3): 193–9. DOI: 10.1007/s00592–009–0109–4. Epub 2009 Mar 31. PMID: 19333547; PMCID: PMC7088164.
17. Hoffmann M., Kleine-Weber H., Schroeder S., et al. SARSCoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. 2020; 181(2): 271–280.e8. https://doi.org/10.1016/j.cell.2020.02.052.
18. Du L., He Y., Zhou Y., et al. The spike protein of SARS-CoV − a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009; 7(3): 226–236. https://doi.org/10.1038/nrmicro2090.
19. Jin-Kui Yang, Shan-Shan Lin, Xiu-Juan Ji & Li-Min Guo. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetologica, pages193–199 (2010). https://doi.org/10.1007/s00592–009–0109–4.
20. Yang J.K., Feng Y., Yuan M.Y. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Chan26 May 2006. https://doi.org/10.1111/j.1464–5491.2006.01861.
21. Liu F., Long X., Zhang B. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. April 22, 2020. https://doi.org/10.1016/j.cgh.2020.04.040.
22. Gupta R., Ghosh A., Singh A.K., Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020 May–Jun; 14(3): 211–212. Epub 2020 Mar 10. PMID: 32172175; PMCID: PMC7102582. https://doi.org/10.1016/j.dsx.2020.03.002.
23. Yang J.K., Feng Y., Yuan M.Y. et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS(Article). https://doi.org/10.1111/j.1464–5491.2006.01861.x
24. Schoen K., Horvat N., Guerreiro N.F. et al. Spectrum of clinical and radiographic findings in patients with diagnosis of H1N1 and correlation with clinical severity. BMC Infect Dis. 2019 Nov 12; 19(1): 964. PMID: 31718571; PMCID: PMC6852716. https://doi.org/10.1186/s12879–019–4592–0.
25. Blanke C.D. In response: Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020 May 26: e3331. Epub ahead of print. PMID: 32452598; PMCID: PMC7267111. https://doi.org/10.1002/dmrr.3331.
26. Bikdeli B., Madhava M.V., Jimenez D. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC Stateof-the-Art Review/ Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2020.04.031
27. Tousoulis D., Papageorgiou N., Androulakis E., Siasos G., Latsios G., Tentolouris K., Stefanadis C. Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. J Am Coll Cardiol. 2013 Aug 20; 62(8): 667–76. PMID: 23948511. https://doi.org/10.1016/j.jacc.2013.03.089.
28. Luo P., Qiu L., Liu Y., et al. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am J Trop Med Hyg. 2020. https://doi.org/10.4269/ajtmh.20–0375.
29. Mendy A., Gopal R., Alcorn J.F., Forno E. Reduced mortality from lower respiratory tract disease in adult diabetic patients treated with metformin. Respirology. 2019; 24(7): 646−651. https://doi.org/10.1111/resp.13486
30. Sharma S., Ray A., Sadasivam B. Metformin in COVID-19: a possible role beyond diabetes. DiabResClinPract. 2020; 164: 108183. https://doi.org/10.1016/j.diabres.2020.108183.
31. Epstein O. The Spatial Homeostasis Hypothesis. Symmetry. 2018; 10: 103. DOI: 10.3390/sym10040103.
32. Воробьев С.В., Петровская Е.Ю. Новый препарат в комплексной терапии сахарного диабета. Пострегистрационный опыт применения у пациентов с СД 1и 2 типа. Медицинский совет. 2018; 16: 28–34 [Vorobev S.V., Petrovskaya E.Yu. A new drug in the complex therapy of diabetes. Post-registration experience of use in patients with type 1 and 2 diabetes. Medical advice. 2018; 16: 28–34 (in Russ.)].
33. Рогова Н.В., Куликова И.В., Стаценко В.И. и др. Сравнительная эффективность антител к С-концевому фрагменту бета-субъединицы рецептора инсулина у больных сахарным диабетом типа 2. Вестник ВолгГМУ. 2011; 1(37): 26–28 [Rogova N.V., Kulikova I.V., Statsenko V.I. et al. Comparative efficacy of antibodies to the C-terminal fragment of the insulin receptor beta-subunit in patients with type 2 diabetes mellitus. VolgGMU Bulletin. 2011; 1(37): 26–28 (in Russ.)].
34. Мкртумян А.М., Воробьев С.В., Волкова А.Р., Ворохобина Н.В. Влияние препарата Субетта на гликемический контроль у пациентов с сахарным диабетом 2 типа: результаты многоцентрового двойного слепого плацебо-контролируемого рандомизированного клинического исследования. Фарматека. — 2020. — Т. 27, № 12. — С. 38–48.
Review
For citations:
Mustafina S.V., Kashirina A.P. Diabetes mellitus in older patients under conditions of novel coronavirus infection (COVID-19). Russian Journal of Geriatric Medicine. 2021;(4):414-419. (In Russ.) https://doi.org/10.37586/2686-8636-4-2021-414-419
Views:
843
Email this article 